Mannkind, Game-Chancer in Sachen Diabetik? (Seite 30)
eröffnet am 11.01.11 13:02:26 von
neuester Beitrag 01.05.24 22:12:10 von
neuester Beitrag 01.05.24 22:12:10 von
Beiträge: 6.832
ID: 1.162.683
ID: 1.162.683
Aufrufe heute: 3
Gesamt: 594.039
Gesamt: 594.039
Aktive User: 0
ISIN: US56400P7069 · WKN: A2DMZL · Symbol: NNFN
4,0830
EUR
+0,10 %
+0,0040 EUR
Letzter Kurs 03.05.24 Tradegate
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 38,27 | +28,16 | |
| 8,0780 | +27,90 | |
| 10,155 | +21,04 | |
| 8,1400 | +20,41 | |
| 3,6100 | +17,51 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6700 | -26,58 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 | |
| 1,7000 | -49,40 | |
| 125,00 | -95,83 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 68.784.584 von price-of-success am 15.07.21 12:32:50Hi, könntest Du bitte heuet die aktuellen VK s einstellen---die Landwirtschaft ruft---vielen Dank vorab 😎🤠
Hab nochmal Nachschlag geholt --- heute gute VK s und ab nach ...orden? 😎🤠
Na hoffentlich stimmt deine These.
Nach Chart rückwärts dürfte es gen 8$ + X gehen? 😎🤠
Immer wieder
habe ich das " Glück" falsch einzukaufen.Es ist paradox, aber jedesmal wenn ich nachlege geht der Kurs kurz darauf Richtung Süden.Das kann schon richtig nervig sein.Gestern bei 3,94 Euro gekauft und Zack, siehe da........
Hoffentlich geht's hier mal richtig zur Sache und über 9 Dollar drüberraus.
Irgendwie prallt bei 4, 60 der Kurs jedesmal ab.
Grüße an alle Investierten.
Trading Spotlight
Das mit dem gap könnte passen das Papier hat eine andere Richtung eingeschlagen so schaut das aus zumindest
Antwort auf Beitrag Nr.: 68.770.019 von pegasusorion am 14.07.21 10:51:00Und wieder aufgestockt 😎🤠
Wir dürften nach Chart heute die 4,46$ anlaufen und dann bin ich gespannt??? 😎🤠
Antwort auf Beitrag Nr.: 68.739.845 von pegasusorion am 10.07.21 10:15:00
Last updated: 7/12/21
11 readers recommend
Type 1
Type 2
Affording Treatment
Insurance
Paying for Treatment
Devices & Technology
Medication
By: Natalie Sainz
Natalie joined the diaTribe Foundation in 2021 after graduating cum laude from Carleton College in 2020 with a degree in Political Science and International Relations.
Medicare has updated its policy to now accept the inhaled insulin Afrezza, as well as injected insulin options to count towards the multiple daily administrations of insulin requirement for continuous glucose monitor coverage.
People with diabetes who are on Medicare will now be able to access continuous glucose monitoring (CGM) if they are using Afrezza as part of their daily multiple insulin dosing regimen (often called multiple daily injections of insulin or MDI). The Centers for Medicare and Medicaid Services (CMS) announced that this new policy will go into effect on July 18 this year.
Previously, people could only gain access to CGM devices if they injected insulin three or more times per day. Therefore, if they were using the inhaled, ultra-rapid-acting insulin (Afrezza) as their mealtime insulin, they could not also have coverage through Medicare for CGM – they were not allowed to use both.
The policy has now been changed – the word injections has been replaced with the word administrations, meaning inhaled insulin now counts as part of the daily multiple insulin dosing regimen required for access to CGM.
Another requirement that people had to meet for their CGM to be reimbursed included the use of a blood glucose meter for at least four fingersticks per day. CMS temporarily updated this policy during the COVID-19 pandemic by eliminating this requirement and recently they announced that they have made this change permanent.
Afrezza is approved for people with type 1 or type 2 diabetes. Its blood-glucose-lowering action peaks just 12 minutes after inhaling the medication, compared to over 30 minutes for typical injected rapid-acting mealtime insulins. You can take Afrezza right as you begin eating, rather than 15-20 minutes before, and this treatment can reduce the risk of low blood sugar (hypoglycemia) later on after meals.
Mannkind
People on Medicare Can Now Access Afrezza and CGM DevicesLast updated: 7/12/21
11 readers recommend
Type 1
Type 2
Affording Treatment
Insurance
Paying for Treatment
Devices & Technology
Medication
By: Natalie Sainz
Natalie joined the diaTribe Foundation in 2021 after graduating cum laude from Carleton College in 2020 with a degree in Political Science and International Relations.
Medicare has updated its policy to now accept the inhaled insulin Afrezza, as well as injected insulin options to count towards the multiple daily administrations of insulin requirement for continuous glucose monitor coverage.
People with diabetes who are on Medicare will now be able to access continuous glucose monitoring (CGM) if they are using Afrezza as part of their daily multiple insulin dosing regimen (often called multiple daily injections of insulin or MDI). The Centers for Medicare and Medicaid Services (CMS) announced that this new policy will go into effect on July 18 this year.
Previously, people could only gain access to CGM devices if they injected insulin three or more times per day. Therefore, if they were using the inhaled, ultra-rapid-acting insulin (Afrezza) as their mealtime insulin, they could not also have coverage through Medicare for CGM – they were not allowed to use both.
The policy has now been changed – the word injections has been replaced with the word administrations, meaning inhaled insulin now counts as part of the daily multiple insulin dosing regimen required for access to CGM.
Another requirement that people had to meet for their CGM to be reimbursed included the use of a blood glucose meter for at least four fingersticks per day. CMS temporarily updated this policy during the COVID-19 pandemic by eliminating this requirement and recently they announced that they have made this change permanent.
Afrezza is approved for people with type 1 or type 2 diabetes. Its blood-glucose-lowering action peaks just 12 minutes after inhaling the medication, compared to over 30 minutes for typical injected rapid-acting mealtime insulins. You can take Afrezza right as you begin eating, rather than 15-20 minutes before, and this treatment can reduce the risk of low blood sugar (hypoglycemia) later on after meals.
Könnte Anfang nächster Woche passieren das Gap Close---dann bin ich wieder dabei---schönes WE 😎🤠
Durchsuchen
Mannkind, Game-Chancer in Sachen Diabetik?
